Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

Federico Monaco, MD, Bart L. Scott, MD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Barry E. Storer, PhD, Frederic Baron, Mary E. Flowers, MD, H. Joachim Deeg, MD, Rainer F. Storb, MD, David G. Maloney, MD PhD, Brenda M. Sandmaier, MD

Blood (2017) 130 (Supplement 1): 908.

https://doi.org/10.1182/blood.V130.Suppl_1.908.908

Published: 2017

Journal Articles

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Huiying Qiu, MD, Brenda M. Sandmaier, MD, Barry E. Storer, PhD, Thomas Chauncey, MD PhD, Finn Petersen, MD, Michael A. Pulsipher, Benedetto Bruno, MD, Mary Flowers, MD, Marco Mielcarek, MD, Rainer Storb, MD, David G Maloney, MD PhD

Blood (2015) 126 (23): 1949.

https://doi.org/10.1182/blood.V126.23.1949.1949

Published: 2015

Journal Articles

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Rachel B Salit, MD, Filippo Milano, MD, PhD, Jonathan A Gutman, MD, Michael B Maris, MD, Thomas Chauncey, MD, PhD, Finn Petersen, M.D., Colleen Delaney, MD, MSc

Blood (2013) 122 (21): 697.

https://doi.org/10.1182/blood.V122.21.697.697

Published: 2013

Journal Articles

Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen

Fabiana Ostronoff, MD, Filippo Milano, MD, PhD, Ted Gooley, Jonathan Gutman, MD, Peter A. McSweeney, MD, Finn Petersen, M.D., Brenda M. Sandmaier, MD, Rainer Storb, MD, Colleen Delaney, MD

Blood (2011) 118 (21): 1943.

https://doi.org/10.1182/blood.V118.21.1943.1943

Published: 2011

Journal Articles

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Blood (2010) 116 (21): 3450.

https://doi.org/10.1182/blood.V116.21.3450.3450

Published: 2010

Journal Articles

A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial.

Brenda M. Sandmaier, MD, Michael Maris, MD, Barry Storer, PhD, Lars Vindelov, MD, Amelia Langston, MD, James C. Wade, MD, MPH, Wolfgang A. Bethge, MD, Michael Pulsipher, MD, Thoralf Lange, MD, Thomas Chauncey, MD, Finn Petersen, MD, Kai Hübel, MD, Ann Woolfrey, MD, Mary E.D. Flowers, MD, David G. Maloney, MD, PhD, Rainer F. Storb, MD

Blood (2009) 114 (22): 348.

https://doi.org/10.1182/blood.V114.22.348.348

Published: 2009

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Blood (2008) 112 (11): 2162.

https://doi.org/10.1182/blood.V112.11.2162.2162

Published: 2008

Journal Articles

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

Blood (2008) 112 (11): 149.

https://doi.org/10.1182/blood.V112.11.149.149

Published: 2008

Journal Articles

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

Drew J. Winston, Jo-Anne H. Young, Vinod Pullarkat, Genovefa A. Papanicolaou, Ravi Vij, Estil Vance, George J. Alangaden, Roy F. Chemaly, Finn Petersen, Nelson Chao, Jared Klein, Kellie Sprague, Stephen A. Villano, Michael Boeckh

Blood (2008) 111 (11): 5403–5410.

https://doi.org/10.1182/blood-2007-11-121558

Published: 2008

Journal Articles

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Blood (2007) 110 (11): 173.

https://doi.org/10.1182/blood.V110.11.173.173

Published: 2007

Journal Articles

Low-Dose Total Body Irradiation (TBI) and Fludarabine Conditioning for Hematopoietic Cell Transplantation (HCT) in Patients with HLA-Class I Mismatched Donors.

Hirohisa Nakamae, Barry Storer, Thomas Chauncey, Michael Pulsipher, Finn Petersen, James C. Wade, Michael Maris, Ben Bruno, Effie Petersdorf, David Maloney, Rainer Storb, Brenda M. Sandmaier

Blood (2007) 110 (11): 3067.

https://doi.org/10.1182/blood.V110.11.3067.3067

Published: 2007

Journal Articles

Pulmonary Changes in Myeloma Patients Following High Dose Melphalan.

Clyde Ford, MD, Robert E. Jensen, PhD, Julie Asch, MD, James E. Pearl, MD, Robert O. Crapo, MD, Finn Petersen, MD

Blood (2006) 108 (11): 2973.

https://doi.org/10.1182/blood.V108.11.2973.2973

Published: 2006

Journal Articles

Prophylaxis Against Cytomegalovirus Infections with Oral Maribavir in Allogeneic Stem Cell Transplant Recipients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Drew Winston, Jo-Anne van Burik, Vinod Pullarkat, Genovefa Papanicolaou, Ravi Vij, Estil Vance, George Alangaden, Roy Chemaly, Finn Petersen, Nelson Chao, Jared Klein, Kellie Sprague, Carolyn Dougherty, Stephen Villano, Michael Boeckh

Blood (2006) 108 (11): 593.

https://doi.org/10.1182/blood.V108.11.593.593

Published: 2006

NARROW

Total Body Irradiation (TBI) Dose Escalation Decreases Risk of Progression and Graft Rejection after Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning for Myelodysplastic Syndrome (MDS) or Myeloproliferative Neoplasms (MPN)

A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience

Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen

Umbilical Cord Blood Transplantation in Patients with Hematological Malignancies Using a Non-ATG Containing Reduced Intensity Preparative Regimen

A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.

Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia

Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study

Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).

Low-Dose Total Body Irradiation (TBI) and Fludarabine Conditioning for Hematopoietic Cell Transplantation (HCT) in Patients with HLA-Class I Mismatched Donors.

Pulmonary Changes in Myeloma Patients Following High Dose Melphalan.

Prophylaxis Against Cytomegalovirus Infections with Oral Maribavir in Allogeneic Stem Cell Transplant Recipients: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only